% | $
Quotes you view appear here for quick access.

OneBeacon Insurance Group, Ltd. Message Board

snogreen 91 posts  |  Last Activity: Jul 11, 2016 1:05 PM Member since: Aug 30, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Dr. Michael Chopp of Henry Ford must be pretty frustrated too. for over 7 years, he and his research staff have dedicated significant time and effort into exploring TB 4 for neuro several areas, like stroke and MS. he has published in many peer reviewed scientific publications. But the poor guy, all he is doing is spinning his wheels. Because RGRX controls the TB 4 heart and neuro..and that means he is stuck with a "broke" penny stock and even worse..stucjk with finkelstein. At some point, I have to wonder if he will just throw up his hands and say (loudly ).."Why bother anymore. They are unable to do a damned single thing with my 7 years work."

    The rot here starts at the top. i'm so glad MANy of you are posting such similar thoughts now too. because I have had my throat "jumped down on", often...for calling Finkel what he is..worthless and destructive. Twenty plus years is enough. he's had his chance..and clearly has blown it, time and time again.

  • Reply to

    Dr. Chopp frustrated too?

    by snogreen May 25, 2016 10:51 AM
    snogreen snogreen May 25, 2016 12:12 PM Flag

    I bet if G Tree's Won S. Yang contolled the TB 4 rights for neuro.....he'd be able to line up funding, a trial design...and FDA appoving such trial...all within about 6-8 months. Finkelstein is just a "deer-in-a-headlight". .....fozen. Dr. Michael Chopp and all his researchers at henry ford would leap right into it and perhaps be the trial center...because I bet that Dr. 'Chopp" is "Chomping" at the bit to get a small trial done in neuro. TB 4 is PHASE 2 ready! Lining up a small preliminary phase 2....maybe 40 patients..would not be that hard or that expensive..henry ford is a neuro center and a research hospital.

  • snogreen snogreen May 26, 2016 9:51 AM Flag

    You're just spitting intyp teh wind. Nothing will happen you ask. It isn't how Finkel operates.

    What SHOULD BE DONE? So simple. Rodman coudl use a boost from his so far bad recommendation. what RGRX shoudl do is set up a trip to NYC. Rodman sets up a coupel one on one visits to big funds. Then Rodman sets up a luncheon and presentation. At this presentation Finkelstein is kept in teh shadow, minimal speaking. Then you have Dr. GOLDSTEIN give an over view to TB 4 and the trial and why it wasn't as bad as many perceive. THEN....if Mr. Won S. Yang of G Tree is based in princeton NJ, you have HIM speak about G Tree's plans, financing for next trial and how upbat he is. THEN you fly in Dr. Michael Chopp of Henry Ford to give a brief summary of his 7 years research of TB 4 in neuro and they are now prepared to start a phase 2 trial when funding available. At teh same time, Dr. Chopp hands each attendee copies of teh abstracts of the about TEN ARTICLES he wrote on his Tb 4 neuro tests. THEN! Goldstein hands out the perhaps DOZEN or so abstracts done in TB 4 heart area. Those main docs are Drs. Riley and Smart, but bases in London.

    If RGRX did this simplke things.which EVERY OTHER BIOTECH DOES SO might see some buyers. Finkelstein has NO CLUE that such luncheoans and talks are STANDARD PRACTICE by soo many biotech. for teh LIFE oif me, I don't know why for 20 years, RGRX has NEVER ONCE has Dr. Goldstein talk at a Wall Stteet meeting. HE IS GOOD! because Joe McNAy jumped on with Goldstein, NOT FINKELSTEIN. And McNay is no dope. finkelstein is.

  • snogreen by snogreen May 26, 2016 11:33 AM Flag

    Too funny, suggest, "Why not e-mail Dr. Goldstein at George Washington University directly and make your suggestions?.

    You know that Finkel and I thus assume this board. You can thus safely assume that Goldstein knows that I have posted for years that Finkel-tinkel is a worthless POS. Following further? we know that Fikelstein's wife -- is Goldstein's COUSIN. So there is this whole nepotism and family gig going on at RGRX. Familes "take care" of family.....liek the mafia....code of the odds of Goldstein giving a da**m are slim to none. At this point they are out for themselves. They are taking what they can out of the company now..and ride on milions and millions of free options we've given them. None of us get paid by RGRX and NONe of us got MILLIONS of free options. So no matter what happens, they win. They just win a lot bigger on a tral win. But their checks come in bi-weekly regardless. And don't forget that for about FIFTEEN YEARS, while RGRX could sell stock and raise milllions ($105 million they spent so far).....Goldstein was DOUBLE DIPPING. he was surely collecting a six figure $$ salary at George Washington Univ...while he ALSO was collecting $150,000 at RGRX....but his REAL full time work was always at GWU.

    So answer is no. Goldstein will not respond to our pleas.

  • snogreen snogreen May 26, 2016 11:52 AM Flag

    Ivchip.....cut Flgeez some slack. he lives in the same area as my very aged mother in FLA... While I cannot post it here....if you knew his age -- how old he was...., you would understand some. He's hopeful that the RGRX shares could be some legacy for his children, as I understand.

  • Hre's another "good funny" a suggestion to email Goldstein....that's a loser. but you wonder:

    " the extent Finkelstein and the Board does read this message board, it certainly does not encourage them to take us seriously."

    You got it all backwards...Since 1987, what is that...about 29 YEARS???? RGRX has spent (blown?) $105,000,00...and for a solid 20 years, as named RGRX and the TB 4 work...shareholders gave EVERY respect to Finkestein and Goldstein. we paid them very well.gave them all the usual benefits...we gifted on them millions of free stock options...and what do we have to show for it? Pretty much every trial was messed up, badly just bad luck. The end results is we have parcelled out significant rights to our "best shot" evidenced by our selling ALL of Canada eye rights for a mere $250,000. They have to pay their salary somehow.

    We took them seriously for 20 years. Now we don't take them seriously. Raisng money with us at 40 cents, with yet another "muddy data" trial....will be extremely hard........and if it can be done, it will include very large dilution and warrants. So right now? I coudl give a damn is they "take us seriously or not". No one on Wall Street takes them seriously.and because of that no one on Wall Street will dig & dig in to what we CAE day 29 effect, cancelling out statistical wins. RGRX explained it all poorly. So down we go, and mgmt just crawled back into their hole and refuses further communication..

  • Reply to

    JJ Should Be Getting Word Out Here

    by bocamp1 May 26, 2016 2:02 PM
    snogreen snogreen May 26, 2016 2:27 PM Flag

    We've done tiny spec bio conferences, for what now....15-20 years? They did nothing for us. we have ONE institutional shareholder.......that's all those 15-20 years of wasted conferences. That one institution has owned about 60,000 for as long as we have.. This conference is no different than all the rest. what WOULD make a difference is this:

    Rodman sets up a luncheon meeting & presentation....Dr. GOLDSTEIN does ALL the TB 4 talking. Overview and questions. Then dr. Michael Chopp of Henry Ford talks about TB 4 and neuro....and he hands out a 50 page document with the 10 or so abstracts of his various tests over the last SEVEN YEARS!. THEN..if he is available (in Princeton NJ?)....Won S. Yang of G tree comes and gives a presentation of what plans G Tree has. At the end of it.,.....RGRX hands out another 50 page document showing the DOZEN or so HEART tests that have bene done with TB 4...many by Drs. Smart and Riley in England.

    FORGET silly conferences. They don't work. Do the above RIFLE SHOT TARGETED invitees... approach direct to BIG bio investors......with Goldstein, dr. M Chopp...Won S. Yang.....and have Finkesltein there only to pass out the heart abstracts binder at the end as people walk out.. This will make Rodman analyst very happy. It will make shareholders happy. You may get real BUYERS of the shares, which makes raisng money "happier & easier".

    Such easy and fantastic idea.....done ALL THE TIME BY OTHER COMPANIES...never crossed Finkels mind. NOT ONCE has Dr. Goldstein EVER talked or presented at a Wall Street INVESTOR conference. Many wall Street analysts are PHD's amd MD's.......Finkel Boob does NOT impress them. Dr. Goldstein would. As woudl dr. Michael Chopp.

  • Reply to

    JJ Should Be Getting Word Out Here

    by bocamp1 May 26, 2016 2:02 PM
    snogreen snogreen May 26, 2016 4:38 PM Flag

    colorton...time is almost up. Reds lights are flashing. If you think RGRX has the LUXURY to sit back and wait and wait and wait and wait for the perfect trial result to "unlock" the value they seek, you're mistaken. We had to give away our USA eye rights to G Tree...if it ever does get approved here (eyes).....RGRX get's only 25% royalty. RGRX so hard up for money, they just gave away ALL Canada rights (eyes) for $250,000. And because mgmt is SO INCAPABLE of getting the story out and explained well.......we are in the $0. 40 cent range. Who is going to buy stock in an offering with yet ANOTHER muddy trial data...while RGRX mgmt twiddles their thumbds watring for the perfect trial result to get "their price". FYI? RGRX is flat out BROKE now!!! No more than 120 days of cash left. For RGRX to SELL STOCK now to raise money to PAY Finkelstein and Goldstein....on ANOTHER muddy trial data..will nessitate selling shares at a big discount to 40 cents and include a large number or warrants. You can wait ALL you want for the "perfect data" to "get your price"......but in the MEANTIME reality sets in and RGRX will have sold OFF many TB 4 rights --- for chump change (like $250k for Canada!!!!) or RGRX dilutes so massivley to raise a mere few million..that WHAT is it worth then, when the "perfect "trial hits? We'll have DILUTEd so massivley and sold OFF all our rights! There isn't much good left. BUYT got that "perfect trial" resukts you wanted...but what good is it now? MAssive dilution done and sold off our Canada. RGHRX should sell out NOW and take back end CVR's.

  • Well that's just peachy keen...... sale of RGRX at 28 cents....even now with a 35 cent print up....our market cap of about 35 million? the trial did not flop by any means.

    way to go finkel Tinkel:

    "What we have here is a failure to communicate".

    Warden to Paul Newman as he put him in the box..Cool Hand Luke.

  • Wel, I'll give Finkel a "single' kudo for trying...this just punlishd comment. Sinilar such efforts by him are non existent.

    What might imprtess the market more woudl be if they saw mgmt, the BOD and G Tre stepping in to BUY stock at 35 cents.

    But FINKELSTEIN. Burn this to memory:

    LUncheon in NYC, with Rodman.
    You do NOT speak.
    Dr' Godl stein takes over all.
    Dr. Chopp comes in and gives neuro talk.
    Dr. Chopp hands out a 50 pahge document of his previous successful tests & abstracts.
    RGRX then givs out another 50 page handout of ALL teh heart tests.
    Then comments from Ora that they CAN design phase 3 without CAE TORTURE.
    SHOW how CAE day 29 wrecked TB4 and OTHER trials.

    Do this you may get some buyers.

  • Reply to

    A complete farce

    by hennypenny686 May 27, 2016 1:14 PM
    snogreen snogreen May 27, 2016 4:38 PM Flag

    there is ALWAYS a "yeah, But" with Finkelstein...............never mentioned dry eye drug....only RGN 352 for heart neuro. Silent in whole PR on RGN 259, and that is key right now..

    His wording also did sound or bode well for possibility of someone like NVS perhaps buying the 'whole cow".

  • Reply to

    The FDA-eye trials-changing endpoints-Aerie Pharma

    by bocamp1 May 28, 2016 7:21 PM
    snogreen snogreen May 29, 2016 9:21 AM Flag

    So what you are telling us is that the FDA lowered the bar on some hurdles for measuring intraocular pressure in Glaucoma, as endpoint hurdle? Lower the bar, better chances success in a disease that cause blindness in many? Good do. But how come you didn't mention that RGRX also has in the recent dry eye trial a tertiary "look see" endpoint of intraocular pressure? While is Finkel Tinkel silent that it was EVEN IN THERE? Why didn't the analyst at Rodman mention it? Why is there silence from RGRX on it? It isn't a big deal. the trial was for dry eye, NOT glaucoma. So it isn't like RGRX will TANK if they tell us. we already tanked. If there was no effect on intraocular pressure, no big deal. if there WAS EFFECT, no matter how small, in intraocular pressure, then that is HUGE..especially in light of the FDA apparently relaxing over the top endpoints of pressure. All we get is silence. I was the only one that caught that tertiary endoint.

  • Reply to

    The FDA-eye trials-changing endpoints-Aerie Pharma

    by bocamp1 May 28, 2016 7:21 PM
    snogreen snogreen May 29, 2016 9:25 AM Flag

    OH...and by the way...RGRX applied for and received USA full patent already for TB 4 in glaucoma. the silence and hiding is wrong. We ALREADY TANKED! Saying there wasn't effect in the pressure measure Day 1 and 29...can't tank us any further.....BUT? IF there was? explosion in price.Easier to raise $$ and new investors.

  • Reply to

    The FDA-eye trials-changing endpoints-Aerie Pharma

    by bocamp1 May 28, 2016 7:21 PM
    snogreen snogreen May 29, 2016 10:20 AM Flag

    Go figure....AERI has a market cap of $454 million. One glaucoma drug and another phase 2. Thats it. In March they reportd some pretty negative SIDE effects of it's lead glaucoma drug...and now you mention moving target endpoints? CAN YOU IMAGINE this..what if TB 4 showed some effect on intraocular pressure and we did that with NO safety issues of NO side effects..and AERI get's a $454 millikon market cap? By all rights then, if TB 4 showed some intraocular pressure reductions from dry eye trial and we did it with NO safety or side effects? RGRX would be at a $200 million market capp very quickly. Maybe more. Money and investors would pour in if there was pressure effects seen, totally safe.

  • Reply to

    Novartis Wants Dry Eye

    by bocamp1 May 29, 2016 4:18 PM
    snogreen snogreen May 29, 2016 4:34 PM Flag

    I just don't see any easy deal between G Tree (regentree) and NVS. G Tree is about 270 million marlet cap? That basically gets you 75% of US and Canada rights for eyes only. RGRX keeps 25%. I don't think NVS will pay $270 million now for that. And I don't see how they ever pay a PREMIUM over that. On other hand? RGRX is $40 million market cap....still owns MANY countries 100% and has 25% USA Canada and slices of Japan, Korea and China. It is also possible TB 4 has Glaucoma application. RGRX still owns 100% of ALL worldwide heart and is a safe drug, no side effects (big) and both heart and neuro are phase 2 need for legnthy pre clinical and tox work..or a Phasse 1. RGRX is the play for NVS...$40 million market cap...not G Tre at 250- 270 million.

  • Reply to

    Heart & Reperfusion

    by grammyellen3 May 30, 2016 12:17 PM
    snogreen snogreen May 30, 2016 3:23 PM Flag

    Neart is a long shot, agreed...but worth a try for a small phase 2. I can show you probably TEN astracts that show TB 4 had GOOD effect in heart area.for every ONe that showed not as much. I think this is only the second "not so good" I've seen. teh DIFFERENCE is this...the GOOD ones, perhaps a dozen of so ocer the years, had full synthetic TB 4 supplied by RGRX (in most cases).. there are people that sell NATURAL TB 4..which is not a posten or good. I am 99.9% sure these peopel did NOT use TB 4 suplied by RGRX, so you have no idea of teh quality....sytnthetic or natural?.nor do they talk of dose levels???...what if they use a natural TB 4..on a dose of won't see much effect. They doio not say.

    pre clicnical wrkr can go far too many ways and depends on who and how it is done and WHAT they USE. This place is not sing TB 4 supplied by RGRX and they do not disclose WHAT they use, where made, natural or synthetic...or doses.

    I also don't see that this research was PEER REVIEWED. Many of Drs. Smart and Riley's wprk was perr reviewed before publication..

    I don't pay this one much heed, at all. I saw it already.

  • Reply to

    Glaucoma: Watch CANF/OPLI in June

    by bocamp1 May 30, 2016 2:25 PM
    snogreen snogreen May 30, 2016 3:36 PM Flag


    "GlobalData estimates that the treatment market for glaucoma in the seven major markets was $2.4 billion in 2013 and will grow to approximately $3 billion by 2023. Most glaucoma drugs on the market today are generic eye drops."

    If most drugs used for glaucoma now are GENERIC eye drops...they have lost patents status...then how valuable is TB 4 if it ever works to reduce pressure? RGRX has recevivd full USA patent for glaucoma. Surely NVS is aware there are no new drugs for glaucoma.if most all are just generically priced eye drops. big market there.

  • Reply to


    by thebasiles777 May 31, 2016 10:53 AM
    snogreen snogreen May 31, 2016 11:11 AM Flag

    I don't think there is any time restriction on Lee's. Too bad there wasn't, we could take them back. It has ben FOUR years now with Lee's. I don't think they had any intetnt to do any trial, until they saw later stage ones done in they coudl then use that info, design on theirs. OR? If teh US one floor, then Lee's halts their plans and save all $$$.

  • Reply to

    50% Haircut Because of Poor Trial Design

    by bocamp1 May 31, 2016 11:35 AM
    snogreen snogreen May 31, 2016 12:08 PM Flag

    Forget about it. Finkelstein is incapable. when we hear about them trying to get funding for RGN 352, heart neuro.....Finkel REALLY means he is waiting on Dr. Chopp to do it all for him. Same goes with eye stuff. Finkel sits and waits for Koreans toi do it all for him. Finkel has every excuse in the book. finkel bought every excuse by Lee's. I'm starting to seriously wonder if G Tree might be relishing the collapse of RGRX shares..and on purpose hide OSDI and glaucoma pressure readings.... if they don't help, RGRX is in trouble. More trouble RGRX get's in...the cheaper the share price. RGRX owns teh WHOLE COW of TB 4 rights...G Tree owns a big "leg". RGRX is worth $36 million. G tree is worth close to $300 million. perhaps all G Tree has to do is left Finkel be typical Finkel...and run RGRX as close to BK as possible..and then G Tree steps a couple dimes a share.

  • Reply to

    50% Haircut Because of Poor Trial Design

    by bocamp1 May 31, 2016 11:35 AM
    snogreen snogreen May 31, 2016 12:12 PM Flag

    HA.who knows..maybe NVS is in cahots with G Tree. All they have to do is let Finkel be Finkel....and RGRX will come very close to BK....thats when they step in.

13.91-0.03(-0.22%)10:13 AMEDT